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Discussion
Dr SongWan (Sha Tin, Hong Kong). Thank you, Dr Rosengart,
for this timely and important study and congratulations for this
elegant presentation.
I have just a few short questions for you. The first question re-
lates to the patient factor. Did all patients continue their aspirin
before operation and through the operating day? If yes, your obser-
vation may not make 100% perfect sense unless you demonstrate
that all the patients actually have the similar responsiveness to
aspirin among all 3 groups.
And in the meantime, the recently published PARADOX study
suggests a nonsmoker had reduced responsiveness to clopidogrel
than smokers. So I just wondered, do you have the data about
smoking status in all these patients, particularly the high function
and the low function groups? Maybe I’d let you answer the first
question.
Dr Rosengart. We did continue aspirin up to the time of use,
which is part of nearly all guidelines in this regard. There is now
apparent consensus that aspirin administration up to the time of
surgery does not increase bleeding risks, but withdrawal in terms
of ACS syndromes does increase the risk of stent thrombosis, so
we continued ASA. We did correct for differences in ASA use
amongst groups in our final analysis, however.
There are, as you point out, a number of causes of the variability
of clopidogrel response, one being smoking; the most significant
cause was genetic heterogeneity in terms of liver metabolism of
the clopidogrel prodrug. This variability is, of course, accounted
for in our analysis using PRU as our input variable.
Dr Wan. And the second question relates to the preoperative
PRU measurement. Were those anesthetists and ICU staff actually
aware of the result? If yes, do you confirm actually the decision for
FFP and platelet transfusion was not biased by that result?
Dr Rosengart. Yes, that’s an important question. This was
retrospective, and in many cases, the surgeon, hopefully in all
cases, the surgeon was aware of the PRU response. In our analysis,
we consequently tried to capture a potential tradeoff between
bleeding and platelet transfusion as a composite adverse outcome
index—essentially, you pick your poison. Either you transfuse
platelets to minimize the bleeding, or try to avoid the platelet trans-
fusion, in which case you have a high chest tube output. This was
the rationale for our looking at a chest tube output, platelet trans-
fusion, in an either/or analysis. In fact, our findings support this as
the outcome of operating on low PRU patients—they are either
transfused or bleed, or in some cases both. What we found is
that you are either giving prophylactic platelet transfusion, which
in many cases was our practice, or looking at what the transfusion
and bleeding rates were and then correcting post hoc.
DrWan.My last question relates to the treatment. Some studies
suggested that tranexamic acid use could actually efficiently
reduce the bleeding in clopidogreltreated patients. So did any pa-
tients in your study receive tranexamic acid? If yes, what about the
duration intraoperatively and how many hours postoperatively?
Dr Rosengart. Nearly all (98%) of our patients received
Amicar. We do not use tranexamic acid.
Dr Wan. Thank you. And I thank the Association for the
privilege of discussing this paper. Thank you.
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